China FDA Tells Sponsors to Verify Trial GCP

Clinical Trials Advisor
A A
Sponsors of new drug applications in China must submit comprehensive data showing adherence to clinical trial requirements by Aug. 25 — in a surprise move that could prompt noncompliant or unprepared companies to withdraw their applications, reducing a pending backlog of more than 1,600.

To View This Article:

Login

Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00